Why topical cosmetic research does not establish injectable benefits
A three-residue copper-binding complex whose topical, microneedle, and injectable claims cannot be pooled
GHK-Cu is a copper complex of the tripeptide glycyl-L-histidyl-L-lysine. Limited topical and laboratory research is often blended online with much broader injectable claims. The routes must be kept separate: topical cosmetic findings do not demonstrate that injected GHK-Cu is safe or effective, and there is no FDA-approved injectable GHK-Cu drug.
Evidence audited · Sources and limitations shown beside each claim
Product and regulatory distinctions
A compound name is not one interchangeable set of instructions. Product, formulation, indication, labeling, and jurisdiction matter.
Injectable GHK-Cu
No FDA-approved injectable GHK-Cu product. FDA identifies compounded injectable GHK-Cu as a potential significant safety risk because of aggregation, peptide-related impurities, immunogenicity, and limited human data.
FDA's May 2026 503A category document lists non-injectable GHK-Cu as under evaluation; this is not FDA approval or a finding of safety and effectiveness.
Copper complex of the tripeptide glycyl-L-histidyl-L-lysine
Chain
3 amino-acid residues coordinated with copper
Formula
C14H24CuN6O4
Molecular weight
403.92 g/mol
GHK-Cu: the amino-acid chain in plain English
A peptide is a chain of amino acids. Read these tiles from left to right: the number is the building block's position, the full name is written out, and the three-letter code is the scientific shorthand.
1GlycineGly
2HistidineHis
3LysineLys
Why the sequence matters
The three-residue peptide binds copper; copper coordination is established chemistry, while broad downstream repair narratives depend on route, formulation, and evidence type.
What the name alone cannot tell you
◆Cu-GHK and the unbound GHK peptide are not identical records.
◆Topical products, microneedle-assisted delivery, and injections create different exposure questions.
Evidence boundary: A biochemical interaction or laboratory carrier result does not establish a cosmetic outcome, a systemic effect, or injectable safety in people.
Use in the real world
How many people use GHK-Cu?
No reliable route-specific population estimate exists.
Cosmetic ingredient use, microneedling, compounded injection, and products merely labeled GHK-Cu are different exposures. Retail listings and social interest do not provide a validated denominator.
Each finding is tied to the population and product actually studied. Trial results are not personal predictions.
Randomized human trial
A small randomized study did not find objective improvement from a GHK-Cu-containing topical regimen after laser resurfacing.
Population
Thirteen patients who completed a randomized comparison after circumoral CO2 laser resurfacing.
Finding
Blinded and computer assessments found no significant between-group improvement in erythema, wrinkles, or overall skin quality, although self-reported satisfaction favored the GHK-Cu regimen.
Limits
The study was very small and tested a multi-product topical regimen after a procedure. It cannot establish injectable effects or broad anti-aging claims.
GHK-Cu delivery through intact skin is limited in an ex vivo laboratory model.
Population
Excised human-skin models, not living trial participants.
Finding
Microneedle pretreatment increased measured peptide and copper permeation compared with intact skin, through which almost none permeated during the experiment.
Limits
Ex vivo penetration does not establish clinical benefit, long-term safety, or equivalence among creams, microneedling, or injection.
Recent cosmetic carrier research is formulation work, not a clinical anti-aging trial.
Population
Laboratory liposome formulations and in-vitro enzyme assays.
Finding
Researchers characterized GHK-Cu-loaded liposomes and observed elastase inhibition in vitro.
Limits
Enzyme inhibition and carrier performance do not demonstrate wrinkle reduction, hair growth, wound healing, systemic benefit, or injection safety in people.
●No adequate human trials establish benefits of injected GHK-Cu for healing, muscle, hair, skin rejuvenation, or longevity.
●Evidence varies by chemical form, carrier, concentration, route, and co-ingredients and should not be pooled as though products were interchangeable.
●Small topical studies and ex vivo skin experiments cannot define systemic safety or effectiveness.
Useful information to organize between visits
✓Whether the product is topical, microneedle-associated, or injectable
✓Complete ingredient list, concentration, product source, and lot
✓Skin or systemic symptoms with onset, severity, duration, and photographs when useful
✓Procedure details if used around laser treatment or microneedling
✓Questions or adverse events to discuss with a dermatologist, clinician, or pharmacist
Questions to bring to a clinician or pharmacist
1.Which findings apply to this exact route and formulation?
2.Is the product a cosmetic or an unapproved drug making treatment claims?
3.What evidence supports sterility, identity, purity, and stability if it is injectable?
4.Could copper exposure, skin barrier disruption, allergies, or other conditions change the risk?
How to use this research profile
This page aggregates regulatory documents and published human research. Its claims, citations, populations, and limitations received an independent editorial evidence check. Last editorial audit: . It has not been medically reviewed by a clinician. It provides general education, not diagnosis, treatment, dosing instructions, or advice for an individual. Use the product-specific official information and consult a qualified clinician or pharmacist for personal decisions.